Crystal Adam sold $137K of TNGX
Crystal Adam (President, R&D) sold 6,140 shares of Tango Therapeutics, Inc. (TNGX) at $22.25 ($0.14M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
Insider selling under a pre-arranged 10b5-1 plan is typically low-signal for fundamentals, but can slightly affect near-term sentiment.
Tango Therapeutics’ R&D President sold 6,140 shares in an open-market transaction disclosed via SEC Form 4.
Likely limited/short-lived impact; any reaction would be more sentiment-driven than fundamental.
Background
The article is an SEC Form 4 insider transaction: Crystal Adam (President, R&D) sold shares under a pre-arranged Rule 10b5-1 plan.
Why it matters
Because the plan is pre-arranged, the disclosure is more useful for monitoring insider behavior than for signaling a new fundamental event.
Market relevance
Traders may briefly reassess sentiment around TNGX, but the 10b5-1 structure limits the signal strength.
Market effects
Minimal; this is company-specific insider activity without new clinical/regulatory or deal information.
None indicated.
None indicated.
Alternative perspectives
Even with a 10b5-1 plan, repeated insider selling can still be read as caution by some traders, especially in thinly traded biotech names.
The sale size ($136.6K) may be routine diversification or tax-related; without context on total holdings or prior sales cadence, directional inference is weak.
Key entities
- issuerTango Therapeutics, Inc.
Subject of the insider transaction disclosure (Form 4) involving an officer’s open-market sale.
- insiderCrystal Adam
President, R&D; sold 6,140 shares on 2026-06-01 under a 10b5-1 plan.
